EQS-Adhoc: Vitruvia Medical AG: successfull capital increase and strengthening of the financial structure
|
EQS-Ad-hoc: Vitruvia Medical AG / Key word(s): Capital Increase/Corporate Action Ad hoc announcement Vitruvia Medical AG December 15, 2025
Vitruvia Medical AG successfully completes capital increase and strengthens its financial structure Vitruvia Medical AG announces that a capital increase was successfully completed on December 15, 2025. The newly created capital was used in full to repay the convertible bond due at the beginning of December. This measure strengthened the company's equity and significantly reduced its debt. The improved capital structure secures the long-term financing of Vitruvia Medical AG and contributes significantly to the company's economic stability. The Board of Directors of Vitruvia AG
End of Inside Information
15-Dec-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Vitruvia Medical AG |
| Kesselackerstr. 18 | |
| 5611 Anglikon | |
| Switzerland | |
| Phone: | +41 44 915 33 78 |
| E-mail: | kontakt@vitruvia-med.com |
| Internet: | www.vitruvia-med.com |
| ISIN: | CH0461931419 |
| WKN: | A2PDWF |
| Listed: | Regulated Unofficial Market in Munich |
| EQS News ID: | 2246030 |
| End of Announcement | EQS News Service |
|
|
2246030 15-Dec-2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 0,00 | 5,60 | 1,97 | 1,42 | 1,75 | 0,00 | 0,00 | |
| EBITDA1,2 | 0,00 | -0,96 | -0,75 | -0,91 | 0,06 | 0,00 | 0,00 | |
| EBITDA-Margin3 | 0,00 | -17,14 | -38,07 | -64,09 | 3,43 | 0,00 | 0,00 | |
| EBIT1,4 | 0,00 | -1,31 | -7,69 | -1,24 | -0,37 | 0,00 | 0,00 | |
| EBIT-Margin5 | 0,00 | -23,39 | -390,36 | -87,32 | -21,14 | 0,00 | 0,00 | |
| Net Profit (Loss)1 | 0,00 | -1,54 | -7,71 | -1,48 | -0,54 | 0,00 | 0,00 | |
| Net-Margin6 | 0,00 | -27,50 | -391,37 | -104,23 | -30,86 | 0,00 | 0,00 | |
| Cashflow1,7 | 0,00 | -0,21 | -0,78 | -0,67 | -0,10 | 0,00 | 0,00 | |
| Earnings per share8 | 0,00 | -0,85 | -4,19 | -0,59 | -0,21 | -0,09 | -0,08 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: BDO
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Vitruvia Medical | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A2PDWF | CH0461931419 | AG | 1,92 Mio € | 11.05.2021 | 8FVC9778+HW | |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -15,30 | 0,00 | 0,00 | -0,31 | 4,03 | -18,47 | 1,10 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 24.06.2024 | 05.08.2025 | 03.05.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -10,94% | -9,14% | -23,50% | -23,50% | -96,62% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
